fluvastatin vs glecaprevir/pibrentasvir
PlainMeds reviewed this comparison against our methodology in August 2026. It places FDA and CMS record fields side by side, without recommending either medication.
Side-by-side comparison of fluvastatin and glecaprevir/pibrentasvir. Data from FDA drug databases (Orange Book, NDC Directory, recalls, shortages) covering 20,000+ approved drugs, plus CMS pricing; see our methodology.
minor Known Drug Interaction
Fluvastatin Pitavastatin ↑ fluvastatin ↑ pitavastatin Coadministration may increase the concentrations of fluvastatin and pitavastatin. Use the lowest approved dose of fluvastatin or pitavastatin.
Lescol
Mavyret
Fluvastatin (Lescol) is a medicine that helps lower cholesterol levels in your blood. It belongs to a group of drugs called statins.
Mavyret is a medicine used to treat hepatitis C (HCV) in adults and children 3 years and older. It contains two drugs, glecaprevir and pibrentasvir, that work together to stop the virus from multiplying.
This medicine is used to lower high cholesterol and triglycerides (fats) in adults and children (10-16 years old) with certain inherited cholesterol problems. It can also lower the risk of needing procedures to improve blood flow to the heart in adults with heart disease. Fluvastatin can also slow down the hardening of arteries in people with heart disease.
Mavyret treats hepatitis C virus (HCV) genotypes 1, 2, 3, 4, 5, or 6. It can be used in people without cirrhosis or with compensated cirrhosis. Mavyret can also treat genotype 1 in people who have already been treated with certain other HCV medicines.
Fluvastatin works by blocking a substance your body needs to make cholesterol. This helps to lower bad cholesterol (LDL) and triglycerides while raising good cholesterol (HDL). By lowering cholesterol, it helps prevent heart disease and stroke.
Mavyret contains glecaprevir and pibrentasvir. Glecaprevir blocks a protein called NS3/4A protease that the virus needs to multiply. Pibrentasvir blocks a protein called NS5A, also needed for the virus to multiply. By blocking these proteins, Mavyret stops the hepatitis C virus from spreading in your body.
- • Headache
- • Upset stomach
- • Muscle pain
- • Abdominal pain
- • Nausea
- • Headache
- • Feeling tired
- • Nausea
- Myalgia 669
- Diarrhoea 371
- Dizziness 361
- Dyspnoea 340
- Nausea 337
- Feeling tired 2,561
- Headache 2,203
- Nausea 1,125
- Itching 653
- Diarrhea 477
This medicine can sometimes cause muscle problems, including rhabdomyolysis (a serious muscle breakdown that can lead to kidney damage). Tell your doctor right away if you have unexplained muscle pain, tenderness, or weakness, especially if you also have a fever or feel sick. This medicine can also cause liver problems. Your doctor should do blood tests to check your liver before you start taking fluvastatin and while you are taking it.
Mavyret can cause hepatitis B to become active again if you have had it in the past. This can cause serious liver problems, including liver failure and death. Your doctor will test you for hepatitis B before you start Mavyret. They will also monitor you during and after treatment.
You should not take fluvastatin if you are pregnant or breastfeeding. This medicine can harm an unborn baby. If you are a woman who could become pregnant, use effective birth control while taking fluvastatin.
It is not known if Mavyret will harm your unborn baby. Talk to your doctor if you are pregnant or plan to become pregnant. It is also not known if Mavyret passes into breast milk. Talk to your doctor about the best way to feed your baby if you are taking Mavyret.
Also Compare, Nearby Drugs
Compare fluvastatin with
How to Read This fluvastatin vs glecaprevir/pibrentasvir Comparison
fluvastatin is classified in the HMG-CoA Reductase Inhibitor (Statin) drug class, while glecaprevir/pibrentasvir sits within the NS3/4A/NS5A Inhibitor (HCV) class. Drugs from different classes work through distinct mechanisms, so a head-to-head comparison illustrates trade-offs rather than equivalence. Both drugs are prescription-only, so a licensed provider must authorize use.
Adverse event totals above are pulled from the FDA's Adverse Event Reporting System (FAERS). For these top-ranked reactions alone, fluvastatin has 2,078 submissions while glecaprevir/pibrentasvir has 7,019. Those figures reflect cumulative reporting volume, not per-patient risk, so older, widely dispensed drugs typically look worse on count alone. These two drugs have a known minor interaction flagged in FDA labeling, attributed to this combination can lead to higher-than-normal levels of fluvastatin in your bloodstream.. Serious warnings, pregnancy guidance, and contraindications can differ even when indications overlap.
A table cannot represent individual circumstances. Data here is sourced from FDA Structured Product Labels (SPL) and FAERS, both of which update as manufacturers and clinicians submit new information. This registry does not provide medical, treatment, substitution, or medication-change directions for fluvastatin or glecaprevir/pibrentasvir.
Registry boundary: This comparison displays source-record fields and does not provide individualized medical direction.